KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Rigel Pharmaceuticals (RIGL) Accumulated Depreciation & Amortization (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Accumulated Depreciation & Amortization data on record, last reported at $2.4 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 2315.0% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, up 2315.0%, while the annual FY2025 figure was $2.4 million, 2315.0% up from the prior year.
  • Accumulated Depreciation & Amortization reached $2.4 million in Q4 2025 per RIGL's latest filing, up from $100000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $2.4 million in Q4 2025 and bottomed at $100000.0 in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $963000.0, with a median of $900000.0 recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 77.78% in 2023, then skyrocketed 2315.0% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.2 million in 2021, then decreased by 25.0% to $900000.0 in 2022, then tumbled by 77.78% to $200000.0 in 2023, then tumbled by 50.0% to $100000.0 in 2024, then surged by 2315.0% to $2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $2.4 million in Q4 2025, $100000.0 in Q4 2024, and $200000.0 in Q4 2023.